Is Arvinas Inc (ARVN) overvalued? · rev $263.4M
Arvinas Inc (ARVN) is a biotechnology company listed on US.
This page asks whether Arvinas Inc (ARVN) looks expensive on cached numbers — not a short thesis.
Latest reported ARVN revenue for 2024-12-31 was $263.4M. Net income was -$198.9M. Revenue was up 235.5% from 2023-12-31 to 2024-12-31. ARVN currently screens at market cap $478.7M.
ARVN currently screens at market cap $478.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ARVN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ARVN stock page for the full model, not this heading.
Not investment advice.